<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>46</viewCount><searchCount>0</searchCount></scores><additional><submitter>Honda R</submitter><funding>Japan Agency for Medical Research and Development</funding><pagination>226-233</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6277182</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(3-4)</volume><pubmed_abstract>Transmissible spongiform encephalopathies (TSEs) are a group of lethal neurodegenerative diseases involving the structural conversion of cellular prion protein (PrP&lt;sup>C&lt;/sup>) into the pathogenic isoform (PrP&lt;sup>Sc&lt;/sup>) for which no effective treatment is currently available. Previous studies have implicated that a polymeric molecule with a repeating unit, such as pentosane polysulfate and polyamidoamide dendrimers, exhibits a potent anti-prion activity, suggesting that poly-(amino acid)s could be a candidate molecule for inhibiting prion propagation. Here, by screening a series of poly-(amino acid)s in a prion-infected neuroblastoma cell line (GT&lt;sup>FK&lt;/sup>), we identified poly-L-His as a novel anti-prion compound with an IC&lt;sub>50&lt;/sub> value of 1.8 µg/mL (0.18 µM). This potent anti-prion activity was specific to a high-molecular-weight poly-L-His and absent in monomeric histidine or low-molecular-weight poly-L-His. Solution NMR data indicated that poly-L-His directly binds to the loop region connecting Helix 2 and Helix 3 of PrP&lt;sup>C&lt;/sup> and sterically blocks the structural conversion toward PrP&lt;sup>Sc&lt;/sup>. Poly-L-His, however, did not inhibit prion propagation in a prion-infected mouse when administered intraperitoneally, suggesting that the penetration of blood-brain barrier and/or the chemical stability of this polypeptide must be addressed before its application in vivo. Taken together, this study revealed the potential use of poly-L-His as a novel treatment against TSEs. (203 words).</pubmed_abstract><journal>Prion</journal><pubmed_title>Poly-L-histidine inhibits prion propagation in a prion-infected cell line.</pubmed_title><pmcid>PMC6277182</pmcid><funding_grant_id>17ek0109075h0003</funding_grant_id><pubmed_authors>Honda R</pubmed_authors><pubmed_authors>Kuwata K</pubmed_authors><pubmed_authors>Elhelaly AE</pubmed_authors><pubmed_authors>Yamaguchi KI</pubmed_authors><pubmed_authors>Fuji M</pubmed_authors><view_count>46</view_count></additional><is_claimable>false</is_claimable><name>Poly-L-histidine inhibits prion propagation in a prion-infected cell line.</name><description>Transmissible spongiform encephalopathies (TSEs) are a group of lethal neurodegenerative diseases involving the structural conversion of cellular prion protein (PrP&lt;sup>C&lt;/sup>) into the pathogenic isoform (PrP&lt;sup>Sc&lt;/sup>) for which no effective treatment is currently available. Previous studies have implicated that a polymeric molecule with a repeating unit, such as pentosane polysulfate and polyamidoamide dendrimers, exhibits a potent anti-prion activity, suggesting that poly-(amino acid)s could be a candidate molecule for inhibiting prion propagation. Here, by screening a series of poly-(amino acid)s in a prion-infected neuroblastoma cell line (GT&lt;sup>FK&lt;/sup>), we identified poly-L-His as a novel anti-prion compound with an IC&lt;sub>50&lt;/sub> value of 1.8 µg/mL (0.18 µM). This potent anti-prion activity was specific to a high-molecular-weight poly-L-His and absent in monomeric histidine or low-molecular-weight poly-L-His. Solution NMR data indicated that poly-L-His directly binds to the loop region connecting Helix 2 and Helix 3 of PrP&lt;sup>C&lt;/sup> and sterically blocks the structural conversion toward PrP&lt;sup>Sc&lt;/sup>. Poly-L-His, however, did not inhibit prion propagation in a prion-infected mouse when administered intraperitoneally, suggesting that the penetration of blood-brain barrier and/or the chemical stability of this polypeptide must be addressed before its application in vivo. Taken together, this study revealed the potential use of poly-L-His as a novel treatment against TSEs. (203 words).</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018</publication><modification>2024-11-08T22:55:44.132Z</modification><creation>2019-08-21T07:00:42Z</creation></dates><accession>S-EPMC6277182</accession><cross_references><pubmed>30074430</pubmed><doi>10.1080/19336896.2018.1505395</doi></cross_references></HashMap>